The Food and Drug Administration (FDA) has approved Dendreon Corporation's Provenge, a "vaccine" that uses a patient's own immune system to fight advanced prostate cancer that is no longer responding to hormone therapy. While not expected to be a cure, the news offers hope to men with advanced disease, many of whom have few treatment options available to them.
It's been a rocky road to approval. In 2007, the FDA refused to approve the initial drug application, requesting more information about whether the drug prolongs survival. In 2009, Dendreon submitted the drug again, this time with more data.
Head on over to cancer.org for the full story.